Administrative/Regulatory
Oct. 20, 2011
Biotechs urge expedited review
Lawyers engaged in fundraising for biotechnology and medical device startups say those companies need less talk and more action to eliminate the regulatory uncertainty that keeps investors away.
Daily Journal Staff Writer
In the past month, President Barack Obama and the U.S. Food and Drug Administration have rolled out blueprints for boosting biomedical innovation and creating new jobs via faster regulatory approvals and outreach to small businesses. But lawyers engaged in venture capital fundraising for biotechnology and medical device startups say those companies need less talk and more action to eliminate regulatory uncerta...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$895, but save $100 when you subscribe today… Just $795 for the first year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In